Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, China.
Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, 430030 Wuhan, China.
Oxid Med Cell Longev. 2021 Aug 31;2021:7958021. doi: 10.1155/2021/7958021. eCollection 2021.
Diabetic kidney disease (DKD) is one of the most common chronic microvascular complications of diabetes; however, there remains a lack of effective therapeutic strategies. Yi Shen Pai Du Formula (YSPDF), a traditional Chinese medicine preparation, has been clinically used in treating chronic kidney disease (CKD) for more than 20 years. However, whether YSPDF has a therapeutic effect on DKD has not been studied.
This study was conducted to investigate the effect of YSPDF administration on mice, a model of type 2 diabetes that develops DKD, and reveal its underlying mechanism of action through a high glucose- (HG-) induced renal injury cell model.
We found that YSPDF significantly improved numerous biochemical parameters (fasting blood glucose, serum creatinine, blood urea nitrogen, 24 h urine total protein, total cholesterol, and total triglycerides) and ameliorated the abnormal histology and fibrosis of renal tissue. Moreover, the status of oxidative stress and levels of inflammatory cytokines (TNF-, IL-6, IL-1, and MCP-1) were markedly inhibited by YSPDF treatment. YSPDF treatment significantly mitigated renal fibrosis, with evidence suggesting that this was by inhibiting epithelial-to-mesenchymal transition (EMT) via suppression of the TGF-1/Smad pathway. Interestingly, the expression of Nrf2, HO-1, and NQO1, proteins known to be associated with oxidative stress, were significantly increased upon administration of YSPDF. The levels of NLRP3 inflammasome proteins, including NLRP3, ASC, caspase-1, and cleaved caspase-1 were decreased in the YSPDF-treated group. Cell experiments showed that YSPDF inhibited EMT and the NLRP3 inflammasome in HG-exposed HK-2 cells, possibly via activation of Nrf2.
Our study indicates that YSPDF may ameliorate renal damage in mice via inhibition of oxidative stress, inflammation, and EMT, with the mechanism potentially being related to the activation of the Nrf2 pathway.
糖尿病肾病(DKD)是糖尿病最常见的慢性微血管并发症之一;然而,目前仍然缺乏有效的治疗策略。益肾排毒方(YSPDF)是一种中药制剂,临床上用于治疗慢性肾脏病(CKD)已有 20 多年。然而,YSPDF 对 DKD 是否有治疗作用尚未研究。
本研究旨在通过高糖(HG)诱导的肾损伤细胞模型,研究 YSPDF 给药对 2 型糖尿病并发 DKD 模型小鼠的作用,并揭示其作用机制。
我们发现 YSPDF 可显著改善多种生化参数(空腹血糖、血清肌酐、血尿素氮、24 小时尿总蛋白、总胆固醇和总甘油三酯),改善肾组织的异常组织学和纤维化。此外,YSPDF 治疗可显著抑制氧化应激状态和炎症细胞因子(TNF-、IL-6、IL-1 和 MCP-1)水平。YSPDF 治疗可显著减轻肾纤维化,这可能是通过抑制 TGF-1/Smad 通路抑制上皮间质转化(EMT)。有趣的是,YSPDF 给药后 Nrf2、HO-1 和 NQO1 等与氧化应激相关的蛋白表达显著增加。YSPDF 治疗组 NLRP3 炎性体蛋白 NLRP3、ASC、caspase-1 和 cleaved caspase-1 的水平降低。细胞实验表明,YSPDF 通过激活 Nrf2 抑制 HG 暴露的 HK-2 细胞中的 EMT 和 NLRP3 炎性体。
本研究表明,YSPDF 可能通过抑制氧化应激、炎症和 EMT 来改善 小鼠的肾损伤,其机制可能与 Nrf2 通路的激活有关。